Format

Send to

Choose Destination
J Nutr. 2015 Apr;145(4):749-57. doi: 10.3945/jn.114.204594. Epub 2015 Feb 18.

Dietary flaxseed independently lowers circulating cholesterol and lowers it beyond the effects of cholesterol-lowering medications alone in patients with peripheral artery disease.

Author information

1
Canadian Center for Agri-Food Research in Health and Medicine, and the Asper Clinical Research Institute, St. Boniface Hospital, Department of Physiology and Pathophysiology, Faculty of Health Sciences.
2
Cardiovascular Research Division, V.I. Lenin University Hospital, Holguin, Cuba.
3
the Asper Clinical Research Institute, St. Boniface Hospital, Department of Surgery, and.
4
Canadian Center for Agri-Food Research in Health and Medicine, and Department of Human Nutritional Sciences, Faculty of Agricultural and Food Sciences, University of Manitoba, Winnipeg, Canada; and gpierce@sbrc.ca aliani@cc.umanitoba.ca.
5
Canadian Center for Agri-Food Research in Health and Medicine, and the Asper Clinical Research Institute, St. Boniface Hospital, Department of Physiology and Pathophysiology, Faculty of Health Sciences, gpierce@sbrc.ca aliani@cc.umanitoba.ca.

Abstract

BACKGROUND:

Dietary flaxseed lowers cholesterol in healthy subjects with mild biomarkers of cardiovascular disease (CVD).

OBJECTIVE:

The aim was to investigate the effects of dietary flaxseed on plasma cholesterol in a patient population with clinically significant CVD and in those administered cholesterol-lowering medications (CLMs), primarily statins.

METHODS:

This double-blind, randomized, placebo-controlled trial examined the effects of a diet supplemented for 12 mo with foods that contained either 30 g of milled flaxseed [milled flaxseed treatment (FX) group; n = 58] or 30 g of whole wheat [placebo (PL) group; n = 52] in a patient population with peripheral artery disease (PAD). Plasma lipids were measured at 0, 1, 6, and 12 mo.

RESULTS:

Dietary flaxseed in PAD patients resulted in a 15% reduction in circulating LDL cholesterol as early as 1 mo into the trial (P = 0.05). The concentration in the FX group (2.1 ± 0.10 mmol/L) tended to be less than in the PL group (2.5 ± 0.2 mmol/L) at 6 mo (P = 0.12), but not at 12 mo (P = 0.33). Total cholesterol also tended to be lower in the FX group than in the PL group at 1 mo (11%, P = 0.05) and 6 mo (11%, P = 0.07), but not at 12 mo (P = 0.24). In a subgroup of patients taking flaxseed and CLM (n = 36), LDL-cholesterol concentrations were lowered by 8.5% ± 3.0% compared with baseline after 12 mo. This differed from the PL + CLM subgroup (n = 26), which increased by 3.0% ± 4.4% (P = 0.030) to a final concentration of 2.2 ± 0.1 mmol/L.

CONCLUSIONS:

Milled flaxseed lowers total and LDL cholesterol in patients with PAD and has additional LDL-cholesterol-lowering capabilities when used in conjunction with CLMs. This trial was registered at clinicaltrials.gov as NCT00781950.

KEYWORDS:

cholesterol lowering; flaxseed; peripheral artery disease; platelet aggregation; statins

PMID:
25694068
DOI:
10.3945/jn.114.204594
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center